Bio-Path Holdings (NASDAQ: BPTH) Dallas Lunch — Tribe Public
Back to All Events

Bio-Path Holdings (NASDAQ: BPTH) Dallas Lunch

  • Truluck's Seafood, Steak and Crab House 2401 McKinney Avenue Dallas, TX, 75201 United States (map)

Bio-Path Holdings (NASDAQ: BPTH) is a clinical stage biotechnology company developing therapeutics for the treatment of cancer and systemic diseases. Bio-Path's RNAi technology for drug development, DNAbilize™, uses a novel liposomal antisense DNA platform that allows for systemic delivery of nucleic acids without toxicity. Using DNAbilize™ clinicians can inhibit the production of proteins involved in cancer and block pathways involved in disease progression.  
 

COMPANY HIGHLIGHTS

  • Proprietary antisense and liposome delivery technology breakthrough for DNA drugs, potentially solving the challenges of delivering these molecules directly to target cells without side effects
  • Original technology licensed from The MD Anderson Cancer Center. Company maintains strong relationship with the Cancer Center
  • Strong IP position with composition of matter and method patents for antisense targets and manufacturing
  • Lead product candidate, prexigebersen (Liposomal Grb2) formerly BP1001, in the clinic for blood cancers and in development for solid tumors. Second product candidate, BP1002 (Liposomal Bcl2) is IND-ready
  • Promising clinical data for BP1001 shows that the drug has been well tolerated with possible anti-leukemic effects, including patients stabilizing for extended treatment